fact

CBL0137 hydrochloride (Curaxin-137 hydrochloride) is an inhibitor of the histone chaperone FACT, which also activates p53 and inhibits NF-κB with EC50 values ​​of 0.37 and 0.47 μM, respectively. CBL0137 hydrochloride functionally inactivates the complex that promotes chromatin transcription (FACT), thereby driving effects on p53 and NF-κB and promoting cancer cell death, and when used in combination with cisplatin, CBL0137 hydrochloride has potent anticancer activity against SCLC.

Defactinib (VS-6063) is a second-generation inhibitor of FAK that inhibits FAK phosphorylation at the Tyr397 site. Defactinib has potential antitumor activity.

(Rel)-Factor B-IN-5 is a complement factor B inhibitor that can be used to study diseases associated with activation of the alternative complement pathway.

Surfactin is a potent cyclic lipopeptide biosurfactants that mediates flux of mono-and divalent cations, such as calcium, across lipid bilayer membranes, with anti-bacterial, anti-fungal, antimycoplasma and hemolytic effects.

Factor B-IN-5 is a complement factor B inhibitor, which can be used to study immune-related diseases.

NFAT Transcription Factor Regulator-1 is a synthesis inhibitor of IL-2 with an IC50 of 182 nM.

Euphorbia factor L25 is a useful organic compound for research related to life sciences and the catalog number is T125089.

Deoxy euphorbia factor L1 is a natural product found in the seeds of Euphorbia lathyris L

Surfactin C2 is a useful organic compound for research related to life sciences. The catalog number is T125603 and the CAS number is 171039-18-2.

Euphorbia factor L24 is a useful organic compound for research related to life sciences and the catalog number is T125685.

Euphorbia factor L22 is a useful organic compound for research related to life sciences and the catalog number is T125686.

Surfactin B1 is a useful organic compound for research related to life sciences. The catalog number is T125988 and the CAS number is 136109-79-0.

Euphorbia factor L9 is a useful organic compound for research related to life sciences and the catalog number is T126086.

Defactinib hydrochloride (PF 04554878 hydrochloride) is a novel inhibitor of FAK. Which inhibits FAK phosphorylation at the Tyr397 site in a time- and dose-dependent manner.

Complement factor D-IN-1 is a potent and selective small-molecule reversible Factor D inhibitor, with IC50 values of 0.006 μM in the FD Thioesterolytic Fluorescent Assay and 0.05 μM in the MAC Deposition Assay.

Spinosad Factor D is a naturally derived fermentation product. It is used as a pesticide against many different insects.

Defactinib analogue-1 (Compound 7) serves as a ligand for the target protein FAK, and is utilized in the synthesis of PROTAC FAK degrader 1.

Preimplantation Factor (PIF-1) exhibits potential activity against graft-versus-host disease (GVHD).

Factumycin is an antibiotic with broad-spectrum antibacterial activity, effective in vitro against both Gram-negative and Gram-positive bacteria. Additionally, Factumycin can serve as a growth promoter in animals.

Anti-virulence factor-IN-2 (compound C7) is an inhibitor targeting the virulence factor KpsM in Escherichia coli. KpsM facilitates the translocation of capsular polysaccharides to the cell surface, enabling KpsM-positive E. coli to evade phagocytosis by the scavenger receptor Marco on liver Kupffer cells, promoting bacterial dissemination. These bacteria can exacerbate ethanol-induced liver disease. Anti-virulence factor-IN-2 demonstrates anti-infective activity by inhibiting KpsM-dependent capsulation in a mouse model of ethanol-induced liver disease. This compound is applicable for alcoholic hepatitis research.

Factor B-IN-6 is an orally bioavailable inhibitor of Factor B. It exhibits significant inhibitory activity on the activation of the human serum alternative pathway. In model animals, Factor B-IN-6 can improve kidney lesions and function, reducing urinary protein levels. Factor B-IN-6 is applicable for kidney disease research.

Factor XI-IN-2 is a Factor XI activation inhibitor with an IC50 of 20 nM. It does not directly inhibit the enzymatic activity of FXIa but specifically binds to the FXI zymogen, allosterically inhibiting the activation process of the FXI zymogen by FXIIa. Factor XI-IN-2 suppresses thrombosis in a rabbit arteriovenous (AV) shunt thrombosis model and can be used in antithrombotic research.

Factor B-IN-7 (Compound (I)) is a selective inhibitor of Factor B. It disrupts the interaction between Factor B and C3b, thereby preventing excessive complement activation. Factor B-IN-7 holds potential for research into complement-mediated diseases such as paroxysmal nocturnal hemoglobinuria (PNH), C3 glomerulopathy, and age-related macular degeneration (AMD).

Anti-virulence factor-IN-3 (Compound 21) is a covalent β-amino sulfone inhibitor of anthrax edema factor (EF), with a Ki of 0.44 μM. It produces an active vinyl sulfone intermediate that forms an irreversible covalent bond with the Lys residue at the EF active site, permanently inhibiting the adenylate cyclase activity of EF. Anti-virulence factor-IN-3 effectively suppresses EF-induced cAMP production, with an EC50 of 0.15 μM, and can be used in the study of anthrax infection.